- $311.82m
- $250.48m
- $39.30m
- 47
- 13
- 73
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.11 | ||
| Price to Tang. Book | 4.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.15% | ||
| Return on Equity | -44.51% | ||
| Operating Margin | -109.69% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.26 | 6.05 | 13.04 | 22.47 | 39.3 | 55.21 | 76.02 | 58.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
Directors
- Nadim Yared PRE (53)
- Jared Oasheim CFO
- Craig Palmer VPR
- Dean Bruhn-Ding VPR
- Liz Galle VPR
- John Brintnall EXO
- Martha Shadan IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 17th, 2000
- Public Since
- June 30th, 2021
- No. of Shareholders
- 68
- No. of Employees
- 200
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 20,927,729
- Address
- 9201 West Broadway Avenue, Suite 650, MINNEAPOLIS, 55445
- Web
- https://www.cvrx.com/
- Phone
- +1 7634162850
- Auditors
- Grant Thornton LLP
Upcoming Events for CVRX
CVRx Inc Annual Shareholders Meeting
CVRx Inc Annual Shareholders Meeting
Q2 2024 CVRx Inc Earnings Release
Similar to CVRX
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the CVRx share price?
As of Today at 19:06 UTC, shares in CVRx are trading at $14.90. This share price information is delayed by 15 minutes.
How has the CVRx share price performed this year?
Shares in CVRx last closed at $14.90 and the price had moved by +56.02% over the past 365 days. In terms of relative price strength the CVRx share price has outperformed the S&P500 Index by +29.83% over the past year.
What are the analyst and broker recommendations for CVRx?
The overall consensus recommendation for CVRx is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the CVRx dividend yield?
CVRx does not currently pay a dividend.
Does CVRx pay a dividend?
CVRx does not currently pay a dividend.
When does CVRx next pay dividends?
CVRx does not currently pay a dividend.
How do I buy CVRx shares?
To buy shares in CVRx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CVRx?
As of the previous close price of $14.90, shares in CVRx had a market capitalisation of $311.82m.
Where are CVRx shares listed?
Here are the trading details for CVRx:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CVRX
What kind of share is CVRx?
Based on an overall assessment of its quality, value and momentum CVRx is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CVRx share price forecast for 2024?
The analyst consensus target price for shares in CVRx is $32.50. That is 118.12% above the last closing price of $14.90.
Analysts covering CVRx currently have a consensus Earnings Per Share (EPS) forecast of -$1.98 for the next financial year.
What is the trend in the CVRx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CVRx. Over the past six months, its share price has underperformed the S&P500 Index by -2.02%.
As of the last closing price of $14.90, shares in CVRx were trading -23.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CVRx PE Ratio?
The CVRx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CVRx?
CVRx's management team is headed by:
- Nadim Yared - PRE
- Jared Oasheim - CFO
- Craig Palmer - VPR
- Dean Bruhn-Ding - VPR
- Liz Galle - VPR
- John Brintnall - EXO
- Martha Shadan - IND